Organon (OGN) Total Non-Current Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Total Non-Current Liabilities of $11.1 billion for Q2 2026, down 4.29% year-over-year from $11.6 billion in Q2 2025, and little changed on a QoQ basis from $11.1 billion in Q1 2026.
Organon (OGN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Organon has reported Total Non-Current Liabilities for 7 years, with the latest figure at $11.1 billion in Q2 2026.
- Total Non-Current Liabilities for Q2 2026 came in at $11.1 billion, down 4.29% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.1 billion (down 4.29% YoY), and the FY2025 annual result was $11.1 billion, down 4.68% from the prior year.
- Total Non-Current Liabilities was little changed at $11.1 billion in Q2 2026, from $11.1 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $11.7 billion in Q4 2023 and troughed at $10.0 billion in Q3 2022.
- A 5-year average of $11.1 billion and a median of $11.2 billion in 2023 frame the typical range for Total Non-Current Liabilities.
- The largest YoY upside for Total Non-Current Liabilities was 30.12% in 2022 against a maximum downside of 7.69% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $11.4 billion in 2022, then climbed by 2.45% to $11.7 billion in 2023, then fell by 0.55% to $11.7 billion in 2024, then declined by 4.68% to $11.1 billion in 2025, then increased by 0.35% to $11.1 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $11.1 billion in Q2 2026, $11.1 billion in Q1 2026, and $11.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.29 Bn | 631.53 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 470.62 Bn | 464.06 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 375.66 Bn | 368.52 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 302.90 Bn | 295.21 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.50 Bn | 252.60 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 237.19 Bn | 223.20 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 182.92 Bn | 179.74 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 160.14 Bn | 148.44 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 11.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.15 Bn |
| Mar 31, 2026 | 11.11 Bn |
| Dec 31, 2025 | 11.11 Bn |
| Sep 30, 2025 | 11.52 Bn |
| Jun 30, 2025 | 11.65 Bn |
| Mar 31, 2025 | 11.62 Bn |
| Dec 31, 2024 | 11.65 Bn |
| Sep 30, 2024 | 11.59 Bn |
| Jun 30, 2024 | 11.46 Bn |
| Mar 31, 2024 | 11.29 Bn |
| Dec 31, 2023 | 11.72 Bn |
| Sep 30, 2023 | 11.18 Bn |
| Jun 30, 2023 | 11.14 Bn |
| Mar 31, 2023 | 10.34 Bn |
| Dec 31, 2022 | 11.44 Bn |
| Sep 30, 2022 | 10.00 Bn |
| Jun 30, 2022 | 10.17 Bn |
| Mar 31, 2022 | 10.14 Bn |
| Dec 31, 2021 | 10.22 Bn |
| Sep 30, 2021 | 10.83 Bn |